Why did PHASQ stock fall 99% on 12 Feb 2026?

PHASQ stock plunged amid thin liquidity, ongoing Chapter 11 restructuring and weak trading interest; volume was only **2,500** shares versus an average of **22,310**, and the PNK listing amplifies volatility.

Is PHASQ stock a buy after the decline?

PHASQ stock remains highly speculative. Meyka AI rates PHASQ **B / HOLD** due to restructuring and clinical risks. Any purchase should factor potential dilution, delisting risk, and lack of institutional coverage.

What catalysts could move PHASQ stock higher?

Positive catalysts include clinical trial milestones for PB2452 or PB1046, restructuring agreements, new capital commitments, or licensing deals. Official filings and sponsor announcements are key triggers.

What is Meyka AI's short‑term forecast for PHASQ stock?

Meyka AI's forecast model projects **USD 0.00050** in 12 months from the current **USD 0.000001**, but this is model‑based and not a guarantee; high uncertainty remains.

US Stocks

PHASQ PhaseBio Pharmaceuticals (PNK) down 99% on 12 Feb 2026: key risks ahead

ByDanny Kontos February 12, 2026

PHASQ stock crashed 99.0% in market hours to USD 0.000001 on 12 Feb 2026, placing PhaseBio Pharmaceuticals, Inc. (PHASQ) among the top losers on the PNK exchange. Trade volume was light at 2,500 shares versus an average of 22,310, underscoring severe liquidity stress. The drop follows a long decline from a 52‑week high of USD 0.0399 and reflects ongoing bankruptcy-era restructuring, negative earnings, and near-zero market cap in the United States market.